Meriva®, a lecithinized curcumin delivery system, in the control of benign prostatic hyperplasia: A pilot, product evaluation registry study

Panminerva Medica

Volumn 54, Issue 4 SUPPL. 1, 2012, Pages 17-22

  Ledda, A ^a   Belcaro, G ^a   Dugall, M ^a   Luzzi, R ^a   Scoccianti, M ^a   Togni, S ^b   Appendino, G ^c   Ciammaichella, G ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b INDENA S P A   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Benign prostatic hyperplasia; Curcumin; IPSS Urinary retention; Meriva ; Prostate

Indexed keywords

CURCUMIN; PHOSPHATIDYLCHOLINE;

AGED; ARTICLE; CHEMISTRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN; MALE; MICTURITION DISORDER; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PILOT STUDY; PROSTATE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE;

AGED; CURCUMIN; DRUG DELIVERY SYSTEMS; HUMANS; LECITHINS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUESTIONNAIRES; URINATION DISORDERS;

EID: 84876556991     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Djavan B, Remzi M, Erne B, Marberger M. The pathophysiology of benign prostatic hyperplasia. Drugs of today. Dec 2002;38(12):867-876.
2. Aggarwal BB. Prostate cancer and curcumin: add spice to your life. Cancer biology & therapy. Sep 2008;7(9): 1436-1440.
3. Sinha R, Anderson DE, McDonald SS, Greenwald P. Cancer risk and diet in India. Journal of postgraduate medicine. Jul-Sep 2003;49(3):222-228.
4. Notara M, Ahmed A. Benign prostate hyperplasia and stem cells: a new therapeutic opportunity. Cell biology and toxicology. Oct 12 2012.
5. Altavilla D, Minutoli L, Polito F, et al. Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia. British journal of pharmacology. Sep 2012;167(1):95-108.
6. Antunes IF, Haisma HJ, Elsinga PH, et al. n Vivo Evaluation of l-0-(4-(2-Fluoroethyl-Carbamoyloxymethyl)-2-Nitrophenyl)-0-beta-d- Glucopyronuronate: A Positron Emission Tomographic Tracer for Imaging beta-Glucuronidase Activity in a Tumor/Inflammation Rodent Model. Molecular imaging. Sep 28 2011.
7. Belcaro G, Cesarone MR, Dugall M, et al. Efficacy and safety of Meriva(R), a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Alternative medicine review : a journal of clinical therapeutic. Dec 2010;15(4):337-344.
8. Belcaro G, Cesarone MR, Dugall M, et al. Product-evaluation registry of Meriva(R), a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva medica. Jun 2010;52(2 Suppl 1):55-62.
9. MarczyloTH, Steward WP, Gescher AJ. Rapid analysis of curcumin and curcumin metabolites in rat biomatrices using a novel ultraper-formance liquid chromatography (UPLC) method. Journal of agricultural and food chemistry. Feb 11 2009;57(3):797-803.
10. Cuomo J, Appendino G, Dern AS, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. Journal of natural products. Apr 25 2011;74(4):664-669.
11. Svatek R, Roche V, Thornberg J, Zimmem P. Normative values for the American Urological Association Symptom Index (AUA-7) and short form Urogenital Distress Inventory (UDI-6) in patients 65 and older presenting for non-urological care. Neurourology and urodynamics. 2005;24(7):606-610.
12. Fanciullacci F, Tagliabue A. [Symptoms of prostatic hypertrophy: evaluation parameters]. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica/ Associazione ricerche in urologia. Feb 1995;67(1):17-20.
13. Glenski WJ, Klee GG, Bergstralh EJ, Oesterling JE. Prostate-specific antigen: establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation, and time on serum concentrations. The Prostate. 1992;21(2):99-110.
14. Dalkin BL, Ahmann FR, Kopp JB. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. The Journal of urology. Dec 1993; 150(6): 1837-1839.
15. Nouri M, Elkhadir K, el Fassi J, et al. [Benign prostatic hypertrophy: clinical and therapeutic aspects. Review of 1,280 cases]. Annates d'urologie. 1999;33(4):243-251.
16. Hofner K. alpha(1)-Blocker therapy in the nineties: focus on the disease. Prostate cancer and prostatic diseases. Dec 1999;2(S4):S9-S15.
17. Kaplan SA, Chung DE, Lee RK, Scofield S, Te AE. A 5-year retrospective analysis of 5alpha-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. International journal of clinical practice. Nov 2012;66(11):1052-1055.
18. Teng L, Jiang C, Sun F, et al. Long-acting formulation of a new muscarinic receptor antagonist for the treatment of overactive bladder. Journal of microencapsulation. Aug 3 2012.
19. Kim HJ, Park JW, Cho YS, et al. Pathogenic role of HIF-1 alpha in prostate hyperplasia in the presence of chronic inflammation. Bio-chimica et biophysica acta. Sep 8 2012.
20. Shi Q, Shih CC, Lee KH. Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity. Anticancer agents in medicinal chemistry. Oct 2009;9(8):904-912.
21. Avonto C, Taglialatela-Scafati O, Pollastro F, et al. An NMR spectroscopic method to identify and classify thiol-trapping agents: revival of Michael acceptors for drug discovery? Angewandte Chemie. Jan 10 2011;50(2):467-471.
22. Gratzke C, Weinhold P, Reich O, et al. Transient receptor potential Al and cannabinoid receptor activity in human normal and hyperplastic prostate: relation to nerves and interstitial cells. European urology. May 2010;57(5):902-910.